Ponatinib-induced psoriasis treated with tildrakizumab.

作者信息

Mueller Kyle, Goldenberg Alicia, Kuraitis Drew

机构信息

Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York.

Department of Dermatology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

出版信息

JAAD Case Rep. 2025 May 28;62:69-71. doi: 10.1016/j.jdcr.2025.04.038. eCollection 2025 Aug.

DOI:10.1016/j.jdcr.2025.04.038

PMID:40678003

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12269876/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c0f/12269876/e334099f3b9f/gr1.jpg

相似文献

[1]

Ponatinib-induced psoriasis treated with tildrakizumab.

JAAD Case Rep. 2025-5-28

[2]

Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy.

Ther Adv Chronic Dis. 2019-8-12

[3]

Impact of tildrakizumab on the quality of life of patients with moderate-to-severe psoriasis: a 36-week prospective monocentric real-life observational study.

Clin Exp Dermatol. 2025-2-24

[4]

Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.

Br J Dermatol. 2015-10-15

[5]

Retrospective Analysis in Patients With Moderate to Severe Plaque Psoriasis Treated With Tildrakizumab: Real-Life Clinical Data.

J Psoriasis Psoriatic Arthritis. 2022-4

[6]

Tildrakizumab Treatment Patterns in Adults With Moderate-to-Severe Plaque Psoriasis: A Retrospective Analysis From the Canadian Patient Support Program.

Dermatol Ther (Heidelb). 2025-5-29

[7]

Patient-Reported Well-Being in Value-Based Routine Care Using Tildrakizumab: 52-week Interim Data of the Phase IV Positive Study.

Psoriasis (Auckl). 2025-6-28

[8]

Tildrakizumab: A Review of Phase II and III Clinical Trials.

Ann Pharmacother. 2018-10-20

[9]

The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis.

Expert Opin Investig Drugs. 2017-2

[10]

Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1).

J Dermatol. 2021-6

本文引用的文献

[1]

Psoriasis in the Era of Targeted Cancer Therapeutics: A Systematic Review on De Novo and Pre-existing Psoriasis in Oncologic Patients Treated with Emerging Anti-neoplastic Agents.

Dermatol Ther (Heidelb). 2024-7

[2]

Targeting IL-17A enhances imatinib efficacy in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia.

Nat Commun. 2024-1-3

[3]

Ponatinib: An update on its drug targets, therapeutic potential and safety.

Biochim Biophys Acta Rev Cancer. 2023-9

[4]

Tyrosine kinase inhibitors can activate the NLRP3 inflammasome in myeloid cells through lysosomal damage and cell lysis.

Sci Signal. 2023-1-17

[5]

Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors.

Dermatol Ther (Heidelb). 2023-2

[6]

Phospholipase A2 enzymes represent a shared pathogenic pathway in psoriasis and pityriasis rubra pilaris.

JCI Insight. 2021-10-22

[7]

Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1.

J Eur Acad Dermatol Venereol. 2021-8

[8]

Tildrakizumab for psoriasis.

Aust Prescr. 2019-2

[9]

Extracellular ATP and IL-23 Form a Local Inflammatory Circuit Leading to the Development of a Neutrophil-Dependent Psoriasiform Dermatitis.

J Invest Dermatol. 2018-6-2

[10]

An IL-17-dominant immune profile is shared across the major orphan forms of ichthyosis.

J Allergy Clin Immunol. 2017-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

新学期，新优惠

Ponatinib-induced psoriasis treated with tildrakizumab.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

推荐工具

Suppr 超能文献